Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Datopotamab Deruxtecan→

Datopotamab Deruxtecan Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2238831-60-0
Molecular formula
Not available
Molecular weight
Not available
Drug class
TROP2-directed antibody–drug conjugate (ADC)topoisomerase I inhibitor payload
Mechanism of action
The antibody binds TROP2 on tumour cells and is internalised. Intracellular cleavage releases a deruxtecan-derived topoisomerase I inhibitor payload, causing DNA damage and tumour-cell death; a membrane-permeable payload can also produce bystander cytotoxicity.
Indications / reported uses
  • Treatment of adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy under the US FDA Datroway indication approved 22 May 2026
  • Treatment of adults with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer after prior EGFR-directed therapy and platinum-based chemotherapy under the earlier US indication; confirm current product label for biomarker and prior-treatment criteria

Sources: US FDA — Datopotamab deruxtecan approval for TNBC, 22 May 2026 · US DailyMed — DATROWAY (datopotamab deruxtecan-dlnk) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Datopotamab Deruxtecan Environmental Risk Assessment (ERA) (the Datopotamab Deruxtecan ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.